Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NF-kappa-B decoy oligonucleotide - AnGes MG

Drug Profile

NF-kappa-B decoy oligonucleotide - AnGes MG

Alternative Names: AMG0101; AMG0102; AMG0103; AMS-001; MP 40; MP 41; MP 42; NDON; NF-kappa-B decoy oligo; NF-kappaB decoy; NF-kB decoy oligo; S-414114; SI-3104

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnGes MG; Osaka University
  • Developer Aichi Gakuin University; AnGes MG; Hosokawa Micron Corporation; Medikit; Morishita Jintan; Nippon Zoki; Osaka University
  • Class Analgesics; Anti-inflammatories; Antipsoriatics; Antirheumatics; Oligonucleotides; Skin disorder therapies
  • Mechanism of Action Genetic transcription modulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase I Back pain
  • No development reported Inflammatory bowel diseases; Intervertebral disc degeneration; Musculoskeletal disorders; Pain; Respiratory tract disorders; Vascular restenosis
  • Discontinued Periodontal disorders; Psoriasis; Spondylosis

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for clinical-Phase-Unknown development in Vascular-restenosis(Prevention) in Japan (Intra-arterial)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Atopic-dermatitis in World (Topical, Ointment)
  • 28 Oct 2019 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top